Interesting Image

Unexpected Metastatic Localizations of Prostate Cancer Determined by ⁶⁸Ga PSMA PET/CT: Series of Four Cases

10.4274/mirt.galenos.2021.41033

• Gözde Mütevelizade
• Ceren Sezgin
• Gül Gümüşer
• Elvan Sayit

Received Date: 02.04.2021 Accepted Date: 16.06.2021 Mol Imaging Radionucl Ther 2022;31(3):223-226 PMID: 36268896

• Abstract
• Full Text
• Video - Image
• References
• 21
• 666

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with overexpression in most prostate cancer cells. Gallium-68-(⁶⁸Ga) PSMA positron emission tomography/computed tomography (PET/CT) imaging is a game-changer in the management of prostate cancer. ⁶⁸Ga PSMA PET/CT scan is advanced and a promising radioligand has high sensitivity in determining lesions of prostate cancer with a high tumor to background ratio. The most common areas of metastasis are the bone and pelvic lymph nodes. The prognosis of prostate cancer is mainly determined by the status of metastases. The presence and the localization of metastases affects treatment planning. In our cases, we presented some examples of uncommon sites of metastases such as the brain, adrenal glands, penis and orbit. Improvements in imaging techniques, such as ⁶⁸Ga PSMA PET/CT have led to the possibility to make more determi nation of rare metastase sites in prostate cancer patients.

Keywords: Prostate cancer, unexpected, metastases, 68Ga PSMA PET/CT

Ethics

Informed Consent: Written informed consent was obtained from the patients who participated in this study.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: G.M., C.S., Concept: G.M., E.S., Design: G.M., G.G., Data Collection or Processing: G.M., C.S., Analysis or Interpretation: G.M., G.G., Literature Search: G.M., E.S., Writing: G.M.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Images

1. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185-1190.
2. Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, Huse J, Rosenblum M, Holodny AI, Young RJ. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging 2014;24:161-166.
3. Dhamija E, Panda A, Das CJ, Gupta AK. Adrenal imaging (part 2): medullary and secondary adrenal lesions. Indian J Endocrinol Metab 2015;19:16-24.
4. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
5. Tatkovic A, McBean R, Schoeman J, Wong D. Prostate penile metastasis: incidence and imaging pattern on 68Ga-PSMA PET/CT. J Med Imaging Radiat Oncol 2020;64:499-504.
6. Saadi A, Kerkeni W, Bouzouita A, Ayed H, Gaja A, Cherif M, Slama RB, Mnif N, Derouiche A, Chebil M. Bilateral orbital metastasis of prostatic adenocarcinoma. Urology 2016;94:e3-4.